A multicenter cohort study evaluates the real-world effectiveness and safety of brentuximab vedotin compared to standard chemotherapy in relapsed or refractory Hodgkin lymphoma.

ClinicalJuly 8, 2026

Brentuximab Vedotin Study in CD30-positive Lymphoma Launched by Takeda

A new study has been initiated to evaluate the safety and usage of brentuximab vedotin in adults with CD30-positive lymphoma.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

— Brentuximab

July 13, 2026 · N/A

Indications

CD30-positive Lymphoma →

Hodgkin Lymphoma →

Therapeutic areas

CD30-positive Lymphoma →

Hodgkin Lymphoma →

Oncology →

Oncology · Hodgkin Lymphoma →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.